Yola Moride will serve the EMEA as a national expert at the EMEA’s London offices. She’s a bigshot. Moride was recently voted president-elect of The International Society for Pharmacoepidemiology (ISPE). She holds appointments as Adjunct Professor at McGill University, Visiting Professor at the University of Bordeaux, and as Project Director at the SMDB Jewish General Hospital in Montreal.

In the announcement about her London appointment, Moride was quoted saying that the European and Canadian systems have surprising similiarities and are likely to converge: “Although Health Canada approves new drugs mainly based on clinical trial data, it is the drug payers—the provinces and private insurers—that are rather well positioned to identify risks seen within their covered populations. In the future, these multiple stakeholders will have to evolve and expand their understanding of the management of health risks related to the consumption of medications.”

Moride added that there could be some cross-pollination from Europe to Canada: “The exchange program with the EMEA will transfer Canadian expertise in pharmaceutical epidemiology to the EU. Canada will benefit by learning the EU’s successful strategies for the deployment of risk management studies across the Canadian Federation. The prescription and medical service databases maintained by each province as part of the public health care payment system are significant resources of risk/benefit data. These should position Canada as a key provider of therapeutic risk management technologies.”